From tariffs and onshoring to MFN, the US has seen significant policy developments - but how will these impact pharma in 2026 ...

Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Strategic Industry Landscape - India Pharmaceutical Industry" report has been added to ResearchAndMarkets.com's offering. The report offers a deep-dive ...

Corcept Therapeutics' strategic shift to relacorilant from Korlym addresses efficacy and safety, amidst Teva's patent dispute. Financially robust with 21.5% YOY revenue growth; however, increasing R&D ...

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between ...

The U.S. pharmaceutical industry underwent a historic, policy-driven transformation in 2025. After a period of post-pandemic cooling, the industry demonstrated stark improvement, ignited by a complex ...

New drug development , the core to success in the pharmaceutical industry has lately become extremely prohibitive because of economic, scientific and regulatory reasons. Major pharmaceutical companies ...

The pharmaceutical commercialization landscape is becoming increasingly complex. Tried and true paradigms for capturing market share and securing reimbursement must evolve in the face of demand for ...

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These ...